Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 303.10K | 204.40K | 159.70K | 188.90K | 433.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 303.10K | 204.40K | 159.70K | 188.90K | 433.70K |
| Cost of Revenue | 140.90K | 95.30K | 66.60K | 82.40K | 112.80K |
| Gross Profit | 162.00K | 108.90K | 92.90K | 106.40K | 320.90K |
| SG&A Expenses | 1.99M | 2.05M | 2.03M | 1.97M | 2.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.13M | 2.21M | 2.17M | 2.28M | 2.35M |
| Operating Income | -1.83M | -2.00M | -2.01M | -2.09M | -1.92M |
| Income Before Tax | -1.97M | -2.12M | -2.14M | -2.20M | -2.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.97 | -2.12 | -2.14 | -2.20 | -2.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.97M | -2.12M | -2.14M | -2.20M | -2.42M |
| EBIT | -1.83M | -2.00M | -2.01M | -2.09M | -1.92M |
| EBITDA | -1.82M | -2.00M | -2.01M | -2.09M | -1.91M |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 530.54M | 530.54M | 530.54M | 530.54M | 530.54M |
| Average Diluted Shares Outstanding | 530.54M | 530.54M | 530.54M | 530.54M | 530.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
